Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nintedanib in Single Lung Transplant for IPF
NCT03562416Phase 2Terminated
- Sponsor
- Temple University
- Start
- Jul 2019
- Primary completion
- Dec 2021
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in idiopathic pulmonary fibrosis (IPF) and Bronchiolitis Obliterans Syndrome (BOS) comparing Nintedanib with Placebo (2 arms). Primary endpoints: Change in Forced Expiratory Volume in 1 Second at 24 months and Change in Forced Vital Capacity at 24 months. Started Jul 2019; status: terminated.
02
Drugs
nintedanib
03
Conditions
idiopathic pulmonary fibrosis (IPF)Bronchiolitis Obliterans Syndrome (BOS)
Beyond the preview
Go deeper on NCT03562416.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03562416.